<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457598</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-401-1757</org_study_id>
    <secondary_id>2015-000834-30</secondary_id>
    <nct_id>NCT02457598</nct_id>
  </id_info>
  <brief_title>Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies</brief_title>
  <official_title>A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety, tolerability,
      pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib
      (ONO/GS-4059) in combination with other targeted anti-cancer therapies in adults with
      relapsed or refractory B-cell lymphoproliferative malignancies.

      This study consists of two parts: Dose Escalation and Dose Expansion. During the dose
      escalation phase, participants will be sequentially enrolled in a standard 3 + 3 dose
      escalation study design, to receive oral tirabrutinib combined with idelalisib entospletinib
      +/- obinutuzumab. The Dose Expansion Phase will enroll additional participants with a single
      B-cell lymphoproliferative malignancy disease type to further evaluate efficacy, safety,
      tolerability, PK, and pharmacodynamics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2015</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Dose Limiting Toxicities (DLTs) During the Dose Escalation Phase</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) at Week 12 During the Dose Expansion Phase for Non-CLL Participants</measure>
    <time_frame>Week 12</time_frame>
    <description>Overall response rate (ORR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) as assessed by disease type.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) at Week 24 During the Dose Expansion Phase for CLL Participants</measure>
    <time_frame>Week 24</time_frame>
    <description>Overall response rate (ORR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) as assessed by disease type.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>PFS is defined as the interval from the start of the study therapy to the earlier of the first documentation of definite disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Participants with Chronic Lymphocytic Leukemia (CLL) Only: Proportion of Participants who Achieve Minimal Residual Negative Disease (&lt; 1 leukemia cell/10,000 leukocytes) During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic (PK) Parameter: AUCtau of tirabrutinib, Idelalisib, Idelalisib Metabolite GS-563117, and Entospletinib During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12 (optional), 24 hours postdose</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic (PK) Parameter: Cmax of tirabrutinib, Idelalisib, Idelalisib Metabolite GS-563117, and Entospletinib During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12 (optional), 24 hours postdose</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">368</enrollment>
  <condition>B-cell Malignancies</condition>
  <arm_group>
    <arm_group_label>Tirabrutinib + idelalisib (Combination I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:
Participants will receive a single dose of tirabrutinib on Day 1 of Cycle 1 and tirabrutinib + idelalisib on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib + idelalisib. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
Dose Expansion:
Additional participants will receive tirabrutinib + idelalisib for a maximum of 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib + entospletinib (Combination II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:
Participants will receive a single dose of tirabrutinib on Day 1 of Cycle 1 and tirabrutinib + entospletinib on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib + entospletinib. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
Dose Expansion:
Additional participants will receive tirabrutinib + entospletinib for a maximum of 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib + idelalisib + obinutuzumab (Combination III)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation:
Participants will receive tirabrutinib + idelalisib + obinutuzumab (doses will depend on results of Combination I data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
Dose Expansion:
Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for a maximum of 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib + entospletinib + obinutuzumab (Combination IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation:
Participants will receive tirabrutinib + entospletinib + obinutuzumab (doses will depend on results of Combination II data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
Dose Expansion:
Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for a maximum of 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single agent tirabrutinib (Combination V)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed or refractory CLL may be enrolled to receive tirabrutinib once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirabrutinib</intervention_name>
    <description>Capsules or tablets administered orally</description>
    <arm_group_label>Tirabrutinib + idelalisib (Combination I)</arm_group_label>
    <arm_group_label>Tirabrutinib + entospletinib (Combination II)</arm_group_label>
    <arm_group_label>Tirabrutinib + idelalisib + obinutuzumab (Combination III)</arm_group_label>
    <arm_group_label>Tirabrutinib + entospletinib + obinutuzumab (Combination IV)</arm_group_label>
    <arm_group_label>Single agent tirabrutinib (Combination V)</arm_group_label>
    <other_name>ONO/GS-4059</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Tablets administered orally twice daily</description>
    <arm_group_label>Tirabrutinib + idelalisib (Combination I)</arm_group_label>
    <arm_group_label>Tirabrutinib + idelalisib + obinutuzumab (Combination III)</arm_group_label>
    <other_name>Zydelig®</other_name>
    <other_name>GS-1101</other_name>
    <other_name>CAL-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entospletinib</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Tirabrutinib + entospletinib (Combination II)</arm_group_label>
    <arm_group_label>Tirabrutinib + entospletinib + obinutuzumab (Combination IV)</arm_group_label>
    <other_name>GS-9973</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Tirabrutinib + idelalisib + obinutuzumab (Combination III)</arm_group_label>
    <arm_group_label>Tirabrutinib + entospletinib + obinutuzumab (Combination IV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic
             lymphoma (SLL), chronic lymphocytic leukemia (CLL) (meeting International Workshop on
             Chronic Lymphocytic Leukemia [IWCLL] Criteria 2008), mantle cell lymphoma (MCL),
             Waldenstrom's macroglobulinemia (WM), or non-germinal center B-cell lymphoma (GCB)
             diffuse large B-cell lymphoma (DLBCL) as documented by medical records on WHO criteria

          -  Prior treatment for FL, MZL, SLL, MCL, WM with ≥ 2 or for CLL or non-GCB DLBCL ≥ 1
             chemotherapy-based or immunotherapy-based regimen, and not transplant eligible and
             have had either progressive disease (PD) or no response to previous treatment

          -  For diseases other than Waldenstrom's macroglobulinemia (WM), presence of
             radiographically measurable presence of ≥ 1 lesion that measures ≥ 2.0 cm in the
             longest dimension (LD) and ≥ 1.0 cm in the longest perpendicular dimension (LPD)

          -  Eastern Cooperative Oncology Group (ECOG) ≤ 2

          -  Platelets ≥ 50 x 10^9/L; Hb ≥ 8.0 g/dL; absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L

          -  Without transfusion and growth factors within 7 days

          -  Aspartate transaminase/alanine transaminase (AST/ALT) ≤ 2.5 x upper limit of normal
             (ULN)

          -  Total bilirubin ≤ 1.5 x ULN

          -  Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min

          -  Not pregnant

          -  Willingness and ability to comply with protocol-specified Pneumocystis jirovecii
             pneumonia (PJP) prophylaxis

        Key Exclusion Criteria:

          -  Hepatitis B surface antigen (HBsAG) positive or hepatitis B core antibody positive

          -  Hepatitis C virus (HCV) antibody positive

          -  History of long QT syndrome or whose corrected QT(QTc) interval measured (Fridericia
             method) at screening is prolonged (&gt;450 ms)

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>401-1757@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania, Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille, Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer-Oncopole I.U.C.T-O</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hosptials NHS Trust, Dept of Haematology</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale Health Board, Clinical Research Facility</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

